Phase 2 Study of Olaparib in Malignant Mesothelioma and Correlation of Efficacy With Germline or Somatic Mutations in BAP1 Gene

INTRODUCTION: PARP inhibition may enhance antitumor responses in BAP1-associated mesothelioma by inducing synthetic lethality. METHODS: A single-center, nonrandomized, phase 2 trial was conducted, in which patients with refractory mesothelioma were given olaparib 300 mg twice daily in a 21-day cycle...

Descripción completa

Detalles Bibliográficos
Autores principales: Ghafoor, Azam, Mian, Idrees, Wagner, Cathy, Mallory, Yvonne, Agra, Maria Garcia, Morrow, Betsy, Wei, Jun S., Khan, Javed, Thomas, Anish, Sengupta, Manjistha, Steinberg, Seth M., Hassan, Raffit
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8502774/
https://www.ncbi.nlm.nih.gov/pubmed/34661178
http://dx.doi.org/10.1016/j.jtocrr.2021.100231

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8502774/
https://www.ncbi.nlm.nih.gov/pubmed/34661178
http://dx.doi.org/10.1016/j.jtocrr.2021.100231

Ejemplares similares